Please login to the form below
Arbutus Biopharma
This page shows the latest Arbutus Biopharma news and features for those working in and with pharma, biotech and healthcare.
Arbutus hit hard as new hep B drug fails on safety
Arbutus shares fell around 25% after the news was announced, despite the company’s protestations that it has other compounds coming through its development pipeline. ... Arbutus’ other candidates in development for HBV include follow-on oral capsid
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
Deal Watch March 2017
In our Top 20 we have only three: Alexion in-licensed the lipid nanoparticle (LNP) technology from Arbutus Biopharma to use as a delivery technology for an mRNA rare disease product ... 90. Arbutus Biopharma. Alexion. Licence. Lipid Nanoparticle (LNP)
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- ASH 2022: bad blood but big advances
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- GSK to submit drug application for new antibiotic to US FDA
- EU outlines measures to mitigate antibiotic shortage across Europe
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
